Infliximab Biosimilar, N297A Mutant | C011P.NA

Catalog No.	C011P.NA
Product Name	Infliximab Biosimilar, N297A Mutant | C011P.NA
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	Anti-TNF alpha Chimeric Monoclonal Antibody
Summary	Recombinant Chimeric IgG1 Monoclonal Antibody.
Isotype	Human IgG1 kappa.
Source/Host	The monoclonal antibody Infliximab biosimilar was produced in the Infliximab biosimilar CHO stable cell line.
Specificity/Sensitivity	The monoclonal antibody Infliximab biosimilar specifically binds to the human TNF alpha.
Form Of Antibody	0.2 uM filtered solution, pH 7.2, no stabilizers or preservatives.
Endotoxin	< 1 EU per 1 mg of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	The Infliximab Biosimilar, N297A Mutant is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Note	Infliximab biosimilar CHO stable cell line is available for licensing to manufacture the Infliximab biosimilar protein.The research grade infliximab biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls are available.
Order Offline	Phone: 1-617-401-8149 Fax: 1-617-606-5022 Email: message@sydlabs.com Orleave a message with a formal purchase order (PO) Or credit card.

Description

C011P.NA: Infliximab Biosimilar, N297A Mutant

Recombinant Chimeric IgG1 Monoclonal Antibody.

Background

Infliximab, a chimeric anti-TNF-α monoclonal antibody, is used to treat psoriasis, Crohn’s disease, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis. Infliximab interferes TNF-α from binding to its receptor in the cell.

Mainly produced by activated macrophages (M1), Tumor necrosis factor (TNF, cachexin, cachectin, tumor necrosis factor alpha, TNFα) plays important roles in the regulation of autoimmune reaction.

Syd Labs also provides the following anti-TNF antibody biosimilar protein:
Adalimumab Biosimilar, research grade

Syd Labs also provides the following research grade antibody biosimilar proteins:
Bevacizumab Biosimilar, research grade (VEGF-A)
Ranibizumab Biosimilar, research grade (VEGF-A, Fab produced in E. coli)
Cetuximab Biosimilar, research grade (HER1, ErbB-1, EGFR)
Panitumumab Biosimilar, research grade (HER1, ErbB-1, EGFR)
Trastuzumab Biosimilar, research grade (HER2, ErbB-2, c-neu)
Pertuzumab Biosimilar, research grade (HER2, ErbB-2, c-neu)
Infliximab biosimilar, research grade (TNF alpha)
Adalimumab biosimilar, research grade (TNF alpha)
Rituximab biosimilar, research grade (CD20)
Denosumab biosimilar, research grade (RANKL, RANK ligand, OPGL, TNFSF11, CD254, TRANCE, ODF)
Palivizumab Biosimilar, research grade (RSV)
Omalizumab biosimilar, research grade (IgE)
Eculizumab biosimilar, research grade (C5)

Please remember our product information: Infliximab Biosimilar, N297A Mutant: C011P.NA Syd Labs

No more offers for this product!